Abstract

Breast cancer is the most common non-skin cancer diagnosed in women. Guidelines recommend that interventions be reserved for women who are most at risk for breast cancer in order to reduce the disease’s burden, conserve resources, and reduce unnecessary treatments. Risk assessment, which includes breast cancer risk factors and risk assessment models, is critical in identifying women who will benefit the most from risk reduction strategies. Shared decision-making principles should guide practitioners in incorporating patients’ values, goals, and objectives in decisions regarding genetic testing, pharmacologic intervention, enhanced surveillance, and other risk-reduction strategies